Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Y Cheung

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Pediatric Blood & Cancer|January 22, 2013
Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastomaIrene Y Cheung, Yi Feng, Nai-Kong V Cheung
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factorIrene Y Cheung, Katharine Hsu, Nai-Kong V Cheung
Cancer|October 16, 2004
Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysisIrene Y Cheung, Arvind Sahota, Nai-Kong V Cheung
International Journal of Cancer|February 2, 2006
Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastomaIrene Y Cheung, Andrew Vickers, Nai-Kong V Cheung
Oncoimmunology|July 3, 2015
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibodyMahiuddin Ahmed, Ming Cheng, Irene Y Cheung, et al.
Cancer Immunology Research|May 20, 2016
Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-EngineeringHong Xu, Hongfen Guo, Irene Y Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapyNai-Kong V Cheung, Irina Ostrovnaya, Deborah Kuk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastomaIrene Y Cheung, Yi Feng, William Gerald, et al.
Cancer Research|July 9, 2009
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumorsHong Xu, Irene Y Cheung, Hong-Fen Guo, et al.
Hybridoma and Hybridomics|February 8, 2003
Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteinsNai-Kong V Cheung, Hong-Fen Guo, Shakeel Modak, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Pediatric Blood & Cancer|January 22, 2013
Early negative minimal residual disease in bone marrow after immunotherapy is less predictive of late or non-marrow relapse among patients with high-risk stage 4 neuroblastomaIrene Y Cheung, Yi Feng, Nai-Kong V Cheung
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2011
Activation of peripheral-blood granulocytes is strongly correlated with patient outcome after immunotherapy with anti-GD2 monoclonal antibody and granulocyte-macrophage colony-stimulating factorIrene Y Cheung, Katharine Hsu, Nai-Kong V Cheung
Cancer|October 16, 2004
Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysisIrene Y Cheung, Arvind Sahota, Nai-Kong V Cheung
International Journal of Cancer|February 2, 2006
Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastomaIrene Y Cheung, Andrew Vickers, Nai-Kong V Cheung
Oncoimmunology|July 3, 2015
Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibodyMahiuddin Ahmed, Ming Cheng, Irene Y Cheung, et al.
Cancer Immunology Research|May 20, 2016
Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-EngineeringHong Xu, Hongfen Guo, Irene Y Cheung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapyNai-Kong V Cheung, Irina Ostrovnaya, Deborah Kuk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastomaIrene Y Cheung, Yi Feng, William Gerald, et al.
Cancer Research|July 9, 2009
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumorsHong Xu, Irene Y Cheung, Hong-Fen Guo, et al.
Hybridoma and Hybridomics|February 8, 2003
Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteinsNai-Kong V Cheung, Hong-Fen Guo, Shakeel Modak, et al.
Pageof 5